Changes of plasma and placental tissue factor pathway inhibitor-2 in women with preeclampsia and normal pregnancy

Thrombosis Research

Volumn 125, Issue 6, 2010, Pages

  Xiong, Yu ^a   Zhou, Qiongjie ^a   Jiang, Fanglin ^c   Zhou, Shufeng ^b   Lou, Yiting ^a   Guo, Qisang ^a   Liang, Wang ^c   Kong, Desheng ^c   Ma, Duan ^a,c   Li, Xiaotian ^a  

^a FUDAN UNIVERSITY   (China)

^b RMIT UNIVERSITY   (Australia)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

preeclampsia; pregnancy; tissue factor pathway inhibitor (TFPI 2)

Indexed keywords

PLACENTA PROTEIN 5; GLYCOPROTEIN; TISSUE-FACTOR-PATHWAY INHIBITOR 2;

ADULT; ARTICLE; BIRTH WEIGHT; CONTROLLED STUDY; FEMALE; FLUOROIMMUNOASSAY; GESTATIONAL AGE; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA; PUERPERIUM; BLOOD; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; METABOLISM; PLACENTA;

ADULT; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GESTATIONAL AGE; GLYCOPROTEINS; HUMANS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY;

EID: 77952584766     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.02.017     Document Type: Article

References (45)

1. MacKay A.P.B., and Atrash H.K. Pregnancy-relatedmortality from preeclampsia and eclampsia. Obstet Gynecol 97 (2001) 533-538
2. Redman C.W., and S.I. Latest advances in understanding preeclampsia. Science 308 (2005) 1592-1594
3. Speake P.F., Glazier J.D., Ayuk P.T., Reade M., Sibley C.P., and D'Souza S.W. L-Arginine transport across the basal plasma membrane of the syncytiotrophoblast of the human placenta from normal and preeclamptic pregnancies. J Clin Endocrinol Metab 88 9 (2003) 4287-4292
4. Vedemikov Y., Saade G.R., and Garfield R.E. Vascular reactivity in preeclampsia. Semin Perinatol 23 1 (1999) 34-44
5. Dekker G.A., and Sibai B.M. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 179 5 (1998) 1359-1375
6. Rampersad R., and Nelson D.M. Trophoblast biology, responses to hypoxia and placental dysfunction in preeclampsia. Front Biosci 12 (2007) 2447-2456
7. Miyagi Y., Koshikawa N., Yasumitsu H., Miyagi E., Hirahara F., et al. cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: identification as placental protein 5 and tissue factor pathway inhibitor-2. J Biochem 116 (1994) 939-942
8. Miyagi Y., K.N., Yasumitsu H., Miyagi E., Hirahara F., Aoki I., et al. cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: identification as placental protein 5 and tissue factor pathway inhibitor-2. J Biochem 116 (1994) 939-942
9. Bohn H., and W.W. Isolation and characterization of the placental protein pp5. Arch Gynakol 223 (1977) 179-186
10. Butzow R., Alfthan H., Stenman U.H., Suikkari A.M., Bohn H., Seppala M., et al. Immunofluorometric demonstration and quantification of placental protein 5 in the absence of pregnancy. Clin Chem 34 8 (1988) 1591-1593
11. Kazama Y., Kamei S., Kuijper J.L., Foster D.C.., Kisiel W., et al. Nucleotide sequence of the gene encoding murine tissue factor pathway inhibitor-2. Thromb Haemost 83 1 (2000) 141-147
12. Tanaka Y., Yasuhiko T., Utsumi J., Matsui M., Sudo T., Nakamura N., et al. Purification, molecular cloning, and expression of a novel growth-promoting factor for retinal pigment epithelial cells, REF-1/TFPI-2. Invest Ophthalmol Vis Sci 45 1 (2004) 245-252
13. Kempaiah P., Chand H.S., and Kisiel W. Human tissue factor pathway inhibitor-2 is internalized by cells and translocated to the nucleus by the importin system. Arch Biochem Biophys 482 1-2 (2009) 58-65
14. Hube F., Pascale R., Sophie I., Sylvie T., Gilles T., and Yves G. Demonstration of a tissue factor pathway inhibitor 2 messenger RNA synthesis by pure villous cytotrophoblast cells isolated from term human placentas. Biol Reprod 68 5 (2003) 1888-1894
15. Obata R. et al, Retinal degeneration is delayed by tissue factor pathway inhibitor-2 in RCS rats and a sodium-iodate-induced model in rabbits. Eye 19 4 (2005) 464-468
16. Gardiner C., Cohen H., Austin S.K., Machin S.J., Mackie I.J., et al. Pregnancy loss, tissue factor pathway inhibitor deficiency and resistance to activated protein C. J Thromb Haemost 4 12 (2006) 2724-2726
17. Iochmann S., Claire B., Valérie C., Annabelle S., Aniça A., Guillaume G., et al. Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion. Clin Exp Metastasis 26 5 (2009) 457-467
18. Negaard H.F.S., Iversen P.O., Østenstad B., Iversen N., Holme P.A., Sandset P.M., et al. Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor. Thromb Haemost 99 6 (2008) 1040-1048
19. Sun Y, Liu M, Xiao Y, Tian L. [Inhibiting effects of TFPI-2 recombinant adenovirus on invasion of laryngeal squamous carcinoma]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2008. 22(7): p. 315-7.
20. Tang Z, Sun ZY, Hu HJ, Xu GL, Chen J, Li JS. [Expression of TFPI-2 gene in pancreatic carcinoma and its prognostic significance]. Zhonghua Zhong Liu Za Zhi, 2008. 30(8): p. 598-601
21. Sierko E., Wojtukiewicz M.Z., and Kisiel W. The role of tissue factor pathway inhibitor-2 in cancer biology. Semin Thromb Hemost 33 7 (2007) 653-659
22. Zusterzeel P.L., V., Peters W.H., Merkus H.W., Nelen W.L., and Steegers E.A. Polymorphism in the glutathione S-transferase P1 gene and risk for preeclampsia. Obstet Gynecol 96 (2000) 50-54
23. Petersen L.C., B.S., Olsen O.H., Nordfang O., Norris F., and Norris K. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor. Eur J Biochem 235 (1996) 310
24. Chinni E., Donatella C., Maurizio M., Corrado R., Rosa Lucia D., Francesco G., et al. Correlation between factors involved in the local haemostasis and angiogenesis in full term human placenta. Thromb Res 122 3 (2008) 376-382
25. Dusse L.M., das Gracas Carvalho M., Cooper A.J., and Lwaleed B.A. Tissue factor and tissue factor pathway inhibitor: a potential role in pregnancy and obstetric vascular complications?. Clin Chim Acta 372 1-2 (2006) 43-46
26. Martinuzzo M. Antiphospholipid antibodies and antibodies to tissue factor pathway inhibitor in women with implantation failures or early and late pregnancy losses. J Thromb Haemost 3 11 (2005) 2587-2589
27. Aharon A., Brenner B., Katz T., Miyagi Y., and Lanir N. Tissue factor and tissue factor pathway inhibitor levels in trophoblast cells: implications for placental hemostasis. Thromb Haemost 92 4 (2004) 776-786
28. Ogawa M., Yanoma S., Nagashima Y., Okamoto N., Ishikawa H., Haruki A., et al. Paradoxical discrepancy between the serum level and the placental intensity of PP5/TFPI-2 in preeclampsia and/or intrauterine growth restriction: possible interaction and correlation with glypican-3 hold the key. Placenta 28 2-3 (2007) 224-232
29. Salem H.T., Westergaard J.G., Hindersson P., Lee J.N., Grudzinskas J.G., Chard T., et al. Maternal serum levels of placental protein 5 in complications of late pregnancy. Obstet Gynecol 95 4 (1982) 467-471
30. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 183 1 (2000) S1-S22
31. Zhang B. the application card of neonatal birthweight in different gestation age from fifteen cities of china. Chin J Pediatr 27 (1989) 316
32. Zhu L., W.J., Mu J., Wang H., Zhang C., Wang J., et al. Expression and characterization of Kunitz domain 3 and C-terminal of human tissue factor pathway inhibitor-2. Acta Biochim Biophys Sin (Shanghai) 41 11 (2009) 948-954
33. Guo H., L.Y., Zhang H., Liu J., Zhang N., Li Y., et al. Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. BMC Mol Biol 3 8 (2007) 110
34. Veronica S., Mona L.G., Daniel S., Kristin M., Karen L.C., et al. Cyclooxygenase-2 Expression Is Related to Nuclear Grade in Ductal Carcinoma in Situ and Is Increased in Its Normal Adjacent Epithelium. Cancer Res 63 (2003) 2347-2350
35. Maryla K., S.K., Epstein *.1., t Ahmed S., Sauvageot J., t Ki Song, et al. Immunohistochemical Analysis of bcl-2, bax, bcl-X and mcl-1 Expression in Prostate Cancers. Am J Pathol 148 5 (1996) 1567-1575
36. Ogawa M., Yanoma S., Nagashima Y., Okamoto N., Ishikawa H., Haruki A., et al. Paradoxical discrepancy between the serum level and the placental intensity of PP5/TFPI-2 in preeclampsia and/or intrauterine growth restriction: possible interaction and correlation with glypican-3 hold the key. Placenta 28 2-3 (2007) 224-232
37. Sprecher C.A., W.K., Mathewes S., and Foster D.C. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci U S A 91 8 (1994) 3353-3357
38. Erlich J., P.G., Fearns C., Muller M., Carmeliet P., Luther T., et al. Tissue factor is required for uterine hemostasis and maintenance of the placental labyrinth during gestation. Proc Natl Acad Sci 96 (1999) 8138-8143
39. Abe K., S.M., Chen J., Bierhaus A., Danave I., Micko C., et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci 96 (1999) 8663-8668
40. Tay S.P., Cheong S.K., and Boo N.Y. Circulating tissue factor, tissue factor pathway inhibitor and D-dimer in umbilical cord blood of normal term neonates and adult plasma. Blood Coagul Fibrinolysis 14 2 (2003) 125-129
41. Stefanec T. How the endothelium and its bone marrow-derived progenitors influence development of disease. Med Hypotheses 62 (2004) 247-251
42. Tempfer C., Z.H., Hefler L., Schatten C., Husslein P., and Kainz C. Serum levels of ELAM-1, but not CD44, predict the clinical outcome of patients with preeclampsia. Hypertens Pregnancy 18 (1999) 45-55
43. Maleka A., b., Bersingera N.A., Di Santob S., Muellera M.D., Sagera R., et al. C-Reactive Protein Production in Term Human Placental Tissue. Placenta 27 (2006) 619-625
44. Schäfer-Somi S. Cytokines during early pregnancy of mammals: a review. Anim Reprod Sci 75 (2003) 73-94
45. Tjoa M.L., J.M.G.v.V., Go A.T.J.J., Blankenstein M.A., Oudejans C.B.M., and van Wijk I.J. Elevated C-reactive protein levels during first trimester of pregnancy are indicative of preeclampsia and intrauterine growth restriction. J Reprod Immunol 59 (2003) 29-37